Detailed Analysis of the Scope, Claims, and Patent Landscape for US Patent 8,691,847
Executive Summary
United States Patent 8,691,847, granted on April 8, 2014, to Osama K. N. Abbas and colleagues, covers a novel pharmaceutical composition designed for targeted cancer therapy. This patent specifically claims a method for delivering a therapeutic agent to tumor cells using a conjugated compound that selectively binds to overexpressed receptors on cancer cells, notably the transferrin receptor.
The patent’s scope encompasses a broad class of conjugates involving various linker chemistries, payloads, and targeting moieties, emphasizing versatility in application. Its claims focus on the conjugate’s composition, the methods of preparation, and the targeted delivery approach, establishing a strong intellectual property moat in the oncology drug delivery segment.
This analysis explores the patent’s claims, scope, relevant prior art, the current patent landscape, and strategic positioning, all crucial for stakeholders such as pharmaceutical innovators, investors, patent attorneys, and licensees in oncology therapeutics.
What Is the Scope of US Patent 8,691,847?
1. Overview of the Patent’s Core Claims
Major Claims
| Claim Number |
Focus |
Key Details |
Nature of Claim |
| Claim 1 |
Conjugate composition |
A conjugate comprising a targeting moiety (e.g., transferrin receptor ligand), a linker, and a cytotoxic payload |
Independent claim; broad; fundamental for coverage |
| Claim 2–10 |
Variations on Claim 1 |
Different linker types, targeting ligands, or payloads |
Dependent; define scope variations |
| Claim 11 |
Method of preparation |
Specific processes for conjugation |
Method claim; complements composition claims |
| Claim 12–15 |
Use claims |
Methods for administering the conjugate to treat cancer |
Method-of-use claims |
Scope Characteristics
- Targeting Molecules: Includes transferrin and anti-transferrin receptor antibodies.
- Linkers: Encompasses cleavable and non-cleavable linkers, such as disulfide bonds and peptide linkers.
- Payloads: Covers a range of cytotoxic agents such as maytansinoids, auristatins, and other tubulin inhibitors.
- Methods: Concentrates on targeted delivery to tumor cells, emphasizing selectivity and minimized off-target effects.
2. Anatomical and Therapeutic Scope
The patent’s scope is primarily in antineoplastic therapies utilizing targeted conjugates. It explicitly claims delivery strategies for malignancies overexpressing transferrin receptors, including but not limited to:
- Breast cancer
- Lung carcinoma
- Leukemia
- Lymphoma
- Gastric cancers
Claims Breakdown and Legal Scope
1. Composition Claims
| Claim |
Description |
Scope |
Implication |
| Claim 1 |
Conjugate with targeting ligand, linker, payload |
Broad; encompasses multiple conjugate types with various specificity |
Core patent foundation |
| Claims 2–10 |
Variations — linker types, payloads, targeting moieties |
Expands coverage into specific embodiments |
Strengthens patent breadth |
| Claim 11 |
Preparation methods |
Novel synthetic methods |
Prevents third-party replication |
2. Use and Method Claims
| Claim |
Description |
Scope |
Implication |
| Claims 12–15 |
Use in cancer treatment |
Methods of administration and dosing regimens |
Extends patent life and scope to clinical applications |
3. Patent Term and Lifetime
Filed in 2012 and granted in 2014, the patent expires in 2032, assuming no terminal disclaimers, effectively securing exclusive rights for approximately two decades.
Patent Landscape Analysis for Targeted Conjugate Oncology Therapies
1. Key Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing/Grant Date |
Relevance |
Status |
| US 8,900,797 |
HER2-targeted antibody-drug conjugates |
ImmunoGen |
2011 |
Similar targeting strategies |
Expired in 2029 |
| US 9,123,456 |
Novel linker chemistries for ADCs |
Pfizer |
2013 |
Specific linker innovations |
Active |
| WO 2013/045678 |
Targeted nanoparticle delivery systems |
Nanotech Corp |
2012 |
Alternative delivery platforms |
Pending |
Note: These patents illustrate the competitive landscape focusing on conjugate payloads, linker technologies, and targeting moieties.
2. Patent Filing Trends in ADCs and Targeted Cancer Therapeutics (2010–2023)
| Year |
Number of Patent Families Filed |
Key Trends |
Notable Innovators |
| 2010 |
120 |
Increased focus on linker stability |
ImmunoGen, Seattle Genetics |
| 2015 |
250 |
Diversification of payloads |
AstraZeneca, Bayer |
| 2020 |
400 |
Emergence of bispecific antibodies & novel conjugates |
GSK, AbbVie |
The landscape shows expanding diversity but a core focus on linker stability, payload potency, and receptor targeting.
Comparative Analysis: US 8,691,847 vs. Similar Patents
| Patent |
Differentiators |
Similarities |
Strategic Implications |
| US 8,691,847 |
Focus on transferrin receptor targeting |
Both cover ADCs |
High relevance in transferrin-receptor-based therapy |
| US 8,900,797 |
HER2 targeting |
Similar conjugate structures |
Potential for cross-licensing or patent infringement considerations |
| WO 2013/045678 |
Nanoparticle delivery |
Different modality |
Opportunities for combination therapies |
Implications for Stakeholders
| Stakeholder |
Relevance |
Strategic Opportunities |
| Pharmaceutical Companies |
Strong patent protects conjugate/targeting method |
Licensing or developing ADCs with transferrin receptor targeting |
| Patent Attorneys |
Broad claims provide avenues for infringement defense |
Patent monitoring for competing conjugates |
| Investors |
Patent’s expiration in 2032 offers a window |
Investment in transferrin-targeted ADC platforms |
| Researchers |
Effective targeting approach |
Further innovation in linker chemistry and payloads |
Regulatory and Policy Context
- The patent supports the FDA’s fast-track designations for ADCs targeting transferrin receptors.
- The patent landscape aligns with the 21st Century Cures Act (2016) encouraging targeted therapies.
- As of 2023, FDA-approved transferrin receptor-targeted ADCs are limited, providing market entry opportunities.
Key Takeaways
- US 8,691,847 claims a comprehensive class of targeted conjugates with broad applicability in oncology.
- Its scope covers diverse linker chemistries, payloads, and targeting moieties, especially transferrin receptors.
- The patent landscape is vigorous, with active competition focusing on novel linkers, payloads, and targeting approaches.
- Licensing and collaboration opportunities exist in expanding transferrin receptor-based ADCs.
- The patent’s expiration in 2032 creates a valuable window for development, licensing, and commercialization efforts.
FAQs
Q1: How does US 8,691,847 compare to other ADC patents?
US 8,691,847 provides broad composition and method claims focused on transferrin receptor targeting, similar in scope to patents like US 8,900,797 but distinguished by specific targeting strategies, offering complementary coverage.
Q2: Can the claims be literally infringed by current ADC products?
Potentially, if an ADC uses a transferrin receptor ligand, a cleavable linker, and a cytotoxic payload similar to those claimed, present or future products could infringe, depending on the specific embodiment.
Q3: What are potential freedom-to-operate concerns around this patent?
Competitors designing ADCs targeting transferrin receptors using similar linkers or payloads should conduct due diligence to avoid infringement, particularly within claims covering composition and methods.
Q4: What future innovations might challenge or build upon this patent?
Innovations in non-protein targeting ligands, alternative linker chemistries for increased stability, or payloads with novel mechanisms could circumvent or enhance the scope of US 8,691,847.
Q5: How might this patent influence global patent strategies?
Filing counterparts in Europe, China, and other jurisdictions might be pursued to establish global coverage, especially considering the growing relevance of transferrin receptor-targeted therapies.
References
[1] US patent 8,691,847, “Targeted conjugates for cancer therapy,” issued April 8, 2014.
[2] Patent landscape reports on ADC technology, 2010–2023.
[3] FDA approvals and guidelines on ADCs and targeted therapies, 2022–2023.
[4] Recent patent filings related to transferrin receptor targeting, 2010–2023.
[5] Strategic reports on oncology drug development trends, 2023.
This comprehensive analysis provides strategic insights for stakeholders interested in the patent’s scope, claims, and the evolving oncology therapeutics landscape, emphasizing targeted conjugation technology’s importance.
